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ABSTRACT
Objective: To investigate the dynamics of IgG1 and IgG4
anti-citrullinated protein antibody (ACPA) subclasses
during anti-tumour necrosis factor (TNF) treatment in
patients with rheumatoid arthritis (RA).
Methods: IgG, IgG1 and IgG4 ACPA levels were
determined by ELISA on anti-citrullinated fibrinogen (ACF)
and IgG1 : IgG4 ACPA ratios were calculated. A pilot
study was performed in 28 ACF-positive patients treated
with infliximab for one year. Confirmation of the results
was obtained using a cohort of 180 consecutive patients
treated with adalimumab for 28 weeks.
Results: The median reduction in ACF levels was 31% for
total IgG, 29% for IgG1, 40% for IgG4 and 22% for the
IgG4 : IgG1 ACF ratio in the infliximab cohort. In
adalimumab-treated patients, ACF levels declined 14% for
total IgG and IgG1, and 36% for IgG4 ACF; the IgG4 : IgG1
ratio was reduced by 24% (all percentage values
p,0.05). The decrease in antibody levels was correlated
with the clinical response; European League Against
Rheumatism good responders had the greatest decline in
antibody levels and this effect was most pronounced for
IgG4 (48% reduction). The IgG4 : IgG1 ACF ratio
preferentially decreased in patients with adequate
therapeutic adalimumab levels.
Conclusion: ACPA subclass distribution is modulated by
effective anti-inflammatory treatment. The preferential
decline of IgG4 ACPA, reflected by the decreased
IgG4 : IgG1 ratio, suggests a beneficial effect of anti-TNF
treatment on chronic antigenic stimulation by citrullinated
proteins. This effect may be directly anti-TNF mediated or
the result of effective dampening of the inflammation in
the rheumatoid joint.
Rheumatoid arthritis (RA) is a chronic inflamma-
tory disease, which may lead to joint destruction.1
One of the characteristics of the disease is the
presence of autoantibodies. Anti-citrullinated pro-
tein antibodies (ACPA) comprise a group of
antibodies highly specific for RA; among those
described are antibodies against cyclic citrullinated
peptide,2 citrullinated fibrinogen,3 citrullinated
alpha-enolase4 and mutated citrullinated vimen-
tin.5 They share a similar high sensitivity and
specificity for RA and are present in early and even
preclinical disease.6 7 A pathophysiological role for
ACPA in RA has been suggested,8 and indeed, in a
serum transfer model of collagen-induced arthritis,
ACPA have been shown to enhance arthritis.9
Two papers have recently reported on ACPA IgG
subclass distribution, with similar results.10 11 Both
show IgG1 as the main IgG subclass, as expected in
a T-helper cell type 1-driven disease. Unexpectedly,
IgG4 anti-citrullinated fibrinogen (ACF) and anti-
cyclic citrullinated peptide antibodies were the
second most frequent IgG subclass. In the latter
paper, differences in isotype usage have been
implied in the transition of undifferentiated
arthritis to RA.11 One explanation for the high
frequency of IgG4 ACPA in RA might be that
during prolonged antigenic stimulation a shift in
the IgG4 : IgG1 antibody ratio occurs that finally
results in an IgG4-dominated response.12–16
The introduction of anti-TNF agents has revo-
lutionised RA treatment, effectively dampening
inflammation in the rheumatic joint.17 Despite its
proposed pathophysiological role in RA, data on
the effect of anti-TNF treatment on ACPA levels in
RA are controversial, because most studies reported
modest or no effect of anti-TNF treatment on IgG
ACPA levels,18–26 and data on the dynamics of IgG4
and IgG1 ACPA subclasses are lacking.
If the presence of IgG4, in the context of IgG1, is
a measure of chronic antigenic stimulation, as
proposed by Aalberse et al,13 a reduction of chronic
antigenic stimulation may lead to a preferential
decrease of IgG4 ACPA. As both IgG1 and IgG4
ACPA levels might be affected by anti-TNF
treatment, the relative contribution of both sub-
classes in an individual patient can best be studied
by calculating the IgG4 : IgG1 ratio.
The aim of the present study was to investigate
the dynamics of predominant ACPA subclasses
during anti-TNF treatment and to relate the
changes in ACPA levels to treatment response.
METHODS
Patients
Two prospective observational study cohorts were
used in the present study. The first cohort
consisted of consecutive RA patients treated with
infliximab for at least one year at Slotervaart
Hospital, Amsterdam, The Netherlands. Twenty-
eight of 51 ACF-positive patients described pre-
viously had serum available for further analyses
(nine non-responders, 15 moderate responders and
four good responders after 46 weeks of treat-
ment).26 Serum was collected on the morning
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before each infusion and stored immediately at 220uC.
Infliximab was administered intravenously at a starting dose
of 3 mg/kg; infusions were given at 0, 2, 6 and 14 weeks and
subsequently at 8-week intervals. In patients with inadequate
response, as judged by the patient’s rheumatologist, the dosage
of infliximab could be increased to 7.5 mg/kg (n = 5).
The second cohort comprised 180 consecutive patients with
RA treated with adalimumab at the Department of
Rheumatology of the Jan van Breemen Instituut, Amsterdam,
The Netherlands. Patients were treated with either adalimumab
and concomitant disease-modifying antirheumatic drugs
(DMARD) or adalimumab alone (most frequently methotrexate
and adalimumab; 136/180 or 75% of patients). All patients used
adalimumab 40 mg subcutaneously every other week. In
patients with an inadequate response, as judged by the treating
rheumatologist, the dosing frequency of adalimumab could be
increased to 40 mg a week (n = 10; seven non-responders, two
moderate and one good responder at the visit before dose
increases; this last observation was carried forward). Serum
samples were collected just before the first injection with
adalimumab at baseline, and at 4, 16 and 28 weeks. The primary
analysis was performed using the samples obtained at baseline
and after 28 weeks of treatment. Five patients had discontinued
treatment after at least 4 weeks and 10 after at least 16 weeks
of follow-up. Among these 15 patients, six were non-respon-
ders, seven moderate responders and two were good responders.
In these patients, the last observation was carried forward.
All patients fulfilled the American College of Rheumatology
1987 revised criteria for RA and had active disease, indicated by
a disease activity score in 28 joints (DAS28) of more than 3.2
despite earlier treatment with two DMARD including metho-
trexate at a dose of 25 mg a week or at the maximal tolerable
dose, according to the Dutch consensus statement on the
initiation and continuation of TNF blocking therapy in RA.27
The study was approved by the local medical ethics committee.
All patients gave written informed consent.
Clinical response
Disease activity was assessed at baseline and after 4, 16 and
28 weeks of treatment using the DAS28 score in the adalimu-
mab cohort and during each infusion in the infliximab cohort.
Clinical response was assessed by the European League Against
Rheumatism (EULAR) criteria.28
Antibody measurements
ACPA IgG antibodies were detected using the ACF ELISA as
described previously.29 For IgG1 and IgG4 ACPA subclass
measurements using this IgG ACF ELISA, the optimal concen-
tration for the mouse, anti-human (MH) monoclonal antibodies
MH161-1 (anti-IgG1, clone HP 6188; Sanquin, Amsterdam, The
Netherlands) and MH164-4 (anti-IgG4, clone HP 6196, Sanquin)
were determined using IgG subclass-specific M proteins. The
monoclonal antibodies used have been evaluated for their
specificity in an International Union of Immunological
Societies/World Health Organization collaborative study.30 31
The specificity of the anti-IgG1 and anti-IgG4 subclass
monoclonal antibodies was confirmed using IgG4 and IgG1
subclass M protein as a coat and different dilutions of the
horseradish peroxidase-labelled monoclonal antibody as the
detecting antibody. Virtually no reactivity was seen with the
anti-IgG4 monoclonal antibody on the IgG1 coat and the anti-
IgG1 monoclonal antibody on the IgG4 coat (data not shown).
Using a 1 : 1 mixture of IgG1 and IgG4 M protein as a coat,
optimal dilutions for the monoclonal antibodies were obtained.
One mg/ml anti-IgG1 and anti-IgG4 gave comparable results to a
concentration of 0.4 mg/ml anti-IgG used in the ACF ELISA (see
supplementary fig 1 available online only).
Sera were titrated in four threefold dilutions, starting at
1 : 50. The antibody concentrations were expressed in arbitrary
units per millilitre (AU/ml) using the previously described
reference serum29 and were calibrated on the linear part of the
calibrator curve. The linear part of the calibrator curves of the
three conjugates was parallel (see supplementary fig 2 available
online only). Total IgG ACF was defined as 1000 AU/ml. As the
concentration of IgG1 is much higher than IgG4, the standard
was arbitrarily defined as containing 1000 AU/ml for IgG1 and
100 AU/ml for IgG4. Coefficients of intra and interassay
variation were below 20% both for the same batch of
citrullinated fibrinogen and for different batches. Cut-off values
for the presence of IgG1 and IgG4 subclasses of ACF antibodies
were defined as the mean plus 2 SD for serum samples obtained
from a group of 40 IgG ACF-negative healthy laboratory
workers. This definition resulted in cut-off values for positivity
of 73 AU/ml for IgG1 and 17 AU/ml for IgG4, respectively (see
supplementary fig 3 available online only). In the adalimumab
cohort, therapeutic adalimumab levels were measured by
ELISA and anti-adalimumab antibodies were measured using a
radioimmunoassay, both as described previously.32
Statistical analysis
The analyses were performed on both cohorts separately using
SPSS version 15.0. Antibody levels were analysed in the positive
patients for each test only. Friedman’s non-parametric repeated
measures comparisons (infliximab cohort) or paired sample t
test (adalimumab cohort) was used to detect changes in ACF
subclass levels in time. A general linear model univariate
analysis with post-hoc Bonferroni test for multiple comparisons
was used to compare the relative change in antibody levels
among the three EULAR response groups. As the arbitrary units
were obtained from parallel calibrator curves, the IgG4 : IgG1
ratio could be calculated in patients positive for both subclasses.
Log transformation to gain normality was applied when
necessary. Geometric means and 95% CI were reported unless
otherwise stated. Pearson’s correlation coefficient was used to
correlate two normally distributed variables.
Table 1 Baseline characteristics of the 180 patients treated with
adalimumab*
Female sex, no of patients (%) 142 (79%)
Age in years, mean (SD) 53 (12)
Disease duration in years, median (IQR) 10 (4–18)
ESR in mm/h, median (IQR) 25 (11–46)
CRP in mg/l, median (IQR) 12 (6–30)
Baseline DAS, mean (SD) 5.1 (1.2)
Erosive disease, no of patients (%) 146 (81%)
Nodular disease, no of patients (%) 49 (27%)
Methotrexate use, no of patients (%) 136 (75%)
Methotrexate dose in mg, median (IQR) 20 (7–25)
ACF IgG positive, no of patients (%) 149 (83%)
ACF IgG1 positive, no of IgG-positive patients (%) 149 (100%)
ACF IgG4 positive, no of IgG-positive patients (%) 108 (79%)
ACF, anti-citrullinated fibrinogen; CRP, C-reactive protein; DAS, disease activity score;
ESR, erythrocyte sedimentation rate; IQR, interquartile range.
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RESULTS
Infliximab cohort
Twenty-eight IgG ACF-positive patients were eligible for
subclass analysis. All patients were positive for IgG1 ACF and
64% (n = 18) of the patients were positive for IgG4 ACF. Total
IgG, IgG1 and IgG4 ACF antibody levels decreased significantly
during the study period. The median IgG ACF levels decreased
from 1182 AU/ml (interquartile range (IQR) 679–3058) at
baseline, 1203 AU/ml (IQR 580–2468) at 14 weeks to 849 AU/
ml (IQR 426–2410) at 46 weeks (p = 0.001). IgG1 ACF levels
decreased from 1320 AU/ml (IQR 679–1321) at baseline,
1374 AU/ml (IQR 577–2686) at 14 weeks to 994 AU/ml (IQR
483–1991) at 46 weeks (p = 0.007). IgG4 ACF levels also
decreased, the median levels were 162 AU/ml (IQR 122–442)
at baseline and 108 AU/ml (IQR 72–223) and 96 AU/ml (IQR
48–227) at 14 and 46 weeks, respectively (p = 0.005).
In terms of percentages, the median decrease from baseline
values at 46 weeks was 31% for IgG, 29% for IgG1 and 40% for
IgG4. The IgG4 : IgG1 ratio decreased with 25% at 14 weeks and
22% at 46 weeks (p = 0.03). Only two patients became negative
for total IgG ACF, one of those also became negative for IgG1.
One other patient became negative for IgG4 ACF levels.
Adalimumab cohort
Baseline characteristics
To substantiate the findings and to investigate whether
treatment response was correlated with changes in antibody
levels, total IgG, IgG1 and IgG4 ACF levels were measured in
180 patients treated with adalimumab, 39 non-responders, 76
moderate and 65 good responders after 28 weeks of treatment.
Table 1 shows the baseline characteristics for the adalimumab-
treated patients.
Figure 1 Antibodies to citrullinated fibrinogen response to adalimumab treatment, stratified for European League Against Rheumatism response. (A)
IgG anti-citrullinated fibrinogen (ACF) mean* values at baseline and at 28 weeks were 988 arbitrary units (AU)/ml (95% CI 118 to 8297) and 905 AU/ml
(69 to 11 812) for non-responders, 1203 AU/ml (52 to 27 980) and 1078 AU/ml (38 to 30 646) for moderate responders and 1284 AU/ml (91 to
18 049) and 1017 AU/ml (69 to 11 812) for good responders, respectively. (B) IgG1 ACF mean* values at baseline and at 28 weeks were 1027 AU/ml
(108 to 9800) and 1011 AU/ml (78 to 13 195) for non-responders, 1340 AU/ml (48 to 37 323) and 1194 AU/ml (42 to 33 922) for moderate
responders and 1653 AU/ml (99 to 27 708) and 1264 AU/ml (85 to 18 692) for good responders, respectively. (C) IgG4 ACF mean* values at baseline
and at 28 weeks were 64 AU/ml (10 to 427) and 53 AU/ml (5 to 577) for non-responders, 174 AU/ml (6 to 5032) and 119 AU/ml (3 to 4842) for
moderate responders and 138 AU/ml (8 to 2404) and 72 AU/ml (3 to 1914) for good responders, respectively. (D) IgG4 : IgG1 ACF ratio mean* values
at baseline and at 28 weeks were 0.045 (0.005 to 0.396) and 0.037 (0.006 to 0.207) for non-responders, 0.066 (0.09 to 0.509) and 0.053 (0.005 to
0.555) for moderate responders and 0.049 (0.006 to 0.390) and 0.035 (0.003 to 0.369) for good responders, respectively. *As these levels were not
normally distributed, geometric means with the 95% CI is reported. Boxes depict the geometric mean with interquartile range, whiskers show 5th to
95th percentiles.
Table 2 Percentage of baseline antibodies to deiminated fibrinogen (ACF) levels after 28 weeks of adalimumab treatment, stratified for EULAR
response*
ACF{ All p Value{ Non-responders Moderate responders Good responders p Value1
ACF IgG 86% (40 to 187) 0.000 92% (35 to 237) 90% (43 to 188) 79% (39 to 161) 0.140
ACF IgG1 86% (34 to 214) 0.000 99% (28 to 352) 89% (42 to 189) 77% (33 to 179) 0.040
ACF IgG4 64% (17 to 250) 0.000 83% (28 to 245) 69% (19 to 245) 52% (12 to 231) 0.022"
Ratio IgG4 : IgG1 ACF 76% (22 to 271) 0.000 80% (15 to 244) 79% (25 to 254) 70% (23 to 223) 0.670
*European League Against Rheumatism (EULAR) response as defined by the EULAR response criteria. {Log transformed to gain normality; geometric mean and 95% CI are reported.
{p Values compared with baseline: one sample t test. 1p Values comparing responder groups: univariate analysis of variance with post-hoc Bonferroni ("p,0.05 for non versus
good responders). ACF, anti-citrullinated fibrinogen.
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Eighty-three per cent of patients were positive for total IgG
ACF antibodies, all of those were also positive for IgG1 ACF and
73% of these patients were positive for IgG4 ACF. Baseline IgG4
ACF levels were associated with treatment response, although
post-hoc Bonferroni analysis only showed significance between
moderate and non-responders (p = 0.03). Baseline IgG and IgG1
levels, as well as the IgG4 : IgG1 ACPA ratio, were similar
among the treatment response groups (see legend to fig 1 for
levels).
ACPA IgG1 and IgG4 levels decrease during anti-TNF treatment
Total IgG, IgG1 and IgG4 ACF antibody levels decreased
significantly during the study period of 28 weeks. The mean
IgG ACF levels decreased from 1186 AU/ml (95% CI 74 to
19 034) at baseline to 1020 AU/ml (95% CI 65 to 15 908) at
28 weeks (p,0.001). IgG1 ACF levels decreased from 1377 AU/
ml (95% CI 72 to 26 486) at baseline to 1181 AU/ml (95% CI 61
to 22 699) at 28 weeks (p,0.001). IgG4 ACF levels also
decreased, the mean levels were 129 AU/ml (95% CI 17 to
2540) at baseline and 83 AU/ml (95% CI 3 to 2213) at 28 weeks
(p,0.001). Only four patients became negative for total IgG
ACF, one of those also became negative for IgG1. Thirteen
patients became negative for IgG4 ACF levels (12%). The mean
IgG4 : IgG1 ACF ratio decreased from 0.055 (95% CI 0.007 to
0.438) to 0.042 (95% CI 0.004 to 0.396; p,0.001), resulting in a
24% reduction after 28 weeks of adalimumab treatment. There
was no difference in change in autoantibody levels between
patients treated with different doses of infliximab (n = 5) or
adalimumab (n = 10; data not shown).
Decrease in antibody levels is associated with response to anti-TNF
treatment
As shown in fig 1, ACF levels decreased significantly after
28 weeks in the moderate (p = 0.02 for total IgG and IgG1 ACF;
p,0.001 for IgG4 ACF) and good responder groups (p,0.001 for
all three antibody levels). In contrast, non-responders did not
show a significant reduction in ACF levels (p = 0.34, 0.90 and
0.13 for total IgG, IgG1 and IgG4 ACF, respectively). The
IgG4 : IgG1 ACF ratio was also significantly reduced in
moderate (p = 0.02) and good (p,0.001) responders, but not
in non-responders (p = 0.24).
To investigate whether the changes in antibody levels were
greater in moderate and good responders compared with non-
responders, ratios of antibody levels at baseline and at 28 weeks
were determined and expressed as percentages. The baseline
antibody level was not correlated with the calculated change
from baseline value (data not shown). As shown in table 2, the
change in IgG1 and IgG4 ACF, but not the decrease in the
IgG4 : IgG1 ratio was significantly different among the
response groups.
Preferential decrease in IgG4 ACF only in the absence of anti-
adalimumab antibodies
Anti-adalimumab antibodies are associated with low levels of
adalimumab.32 Therefore, we expected the IgG4 : IgG1 ratio
only to decrease in those patients without anti-adalimumab
antibodies (when adequate levels of adalimumab are present).
Indeed, as shown in fig 2, the mean IgG4 : IgG1 ratio did not
change in the group of patients with anti-adalimumab
antibodies (median adalimumab level 1.4 mg/l, IQR 0.0–5.1),
whereas in the group of patients without anti-adalimumab
antibodies (median adalimumab level 10.9 mg/l, IQR 7.6–14.5),
a mean 28% decrease in the IgG4 : IgG1 ratio was observed
(p = 0.04).
Decrease in ACPA levels is not correlated with total immunoglobulin
levels
To explore the possibility that a decrease in ACPA levels is
merely a reflection of a decrease in total immunoglobulin levels,
IgG, IgG1 and IgG4 levels were measured in 10 patients who
showed the greatest decline in ACPA levels. There was no
correlation between a decline in ACPA levels and total
immunoglobulin levels after 28 weeks of adalimumab treatment
(R = 20.19, p = 0.604 for IgG, R = 0.21, p = 0.57 for IgG1
and R = 0.34, p = 0.33 for IgG4; see supplementary fig 4
available online only).
DISCUSSION
The aim of our study was to investigate the dynamics of IgG1
and IgG4 ACPA subclasses in RA patients treated with the TNF-
blocking agents adalimumab and infliximab. The decrease in
ACPA levels of all subclasses was correlated with treatment
response. A preferential decline of IgG4 ACPA as reflected by a
decrease in the IgG4 : IgG1 ACPA ratio was observed and was
most pronounced in patients with adequate anti-TNF levels.
The frequencies of IgG4 ACPA-positive patients in our
cohorts were higher than those reported by Chapuy-Regaud et
al,10 but lower than those reported by Verpoort et al.11
Dissimilarity in patient cohorts ((early) RA compared with
established RA patients eligible for anti-TNF treatment), the
different assays and corresponding determination of cut-off
values may account for the variation in reported frequencies.
Our findings substantiate and extend previous data on ACPA
levels in RA patients after anti-TNF treatment.18–26 One study
reported a decrease in the presence and levels of IgG4 ACPA
after 7 years of follow-up in early arthritis patients,11 but
detailed data on treatment strategies in these patients were
lacking. The direct effect of treatment on IgG4 ACPA levels had
not been studied previously.
The pronounced effect seen on IgG4 antibody levels may be a
direct effect of TNFa inhibition on IgG4 production. TNFa has
been shown to modulate class switch recombination because
blocking TNFa antibodies interfere with the co-stimulatory
signal provided by T cells needed for IL-4-induced IgG4
Figure 2 Percentage of baseline IgG4 : IgG1 anti-citrullinated
fibrinogen ratio* after 28 weeks of adalimumab treatment, stratified for
the presence of anti-adalimumab antibodies. Mean* IgG4 : IgG1 ratio at
baseline and at 28 weeks was 72% (95% CI 21 to 248) and 100% (95%
CI 27 to 367) for patients without and with anti-adalimumab antibodies.
*As this ratio was not normally distributed, geometric mean with 95% CI
are reported. Boxes depict geometric mean with interquartile range,
whiskers show 5th to 95th percentiles.
Extended report
Ann Rheum Dis 2009;68:558–563. doi:10.1136/ard.2008.088401 561
synthesis.33 A reduction of specific ACPA IgG4 would then just
be a reflection of a decrease in total IgG4 levels. As changes in
total IgG4 and specific IgG4 were not correlated, this hypothesis
seems less likely.
The differentiated response of IgG1 and IgG4 ACPA levels
may also be caused by the anti-inflammatory effect of anti-TNF
treatment, as is suggested by the preferential decrease in those
responding to anti-TNF treatment. As long-term chronic
stimulation is needed for a pronounced IgG4 response,13 IgG4
APCA levels might reflect chronic antigenic stimulation by
citrullinated proteins.8 A decrease in IgG4 ACPA might thus
reflect the disruption of the chronic stimulation by citrullinated
proteins and subsequent interaction with ACPA by effective anti-
inflammatory treatment, because citrullination is inflammation
dependent.34 35 To gain further insight into this hypothesis, it
would be interesting to correlate changes in the IgG4 : IgG1
ACPA ratio with a reduction in synovial antigenic load (ie, the
amount of citrullinated proteins) during anti-TNF treatment.
The differential response for IgG1 and IgG4 may provide
insight into the nature of the immune response leading to the
production of these antibodies. IgG1 ACPA may be predomi-
nantly produced by long-lived plasma cells, whereas IgG4 ACPA
may arise by the continuous generation of short-lived plasma
cells from memory B cells, a process that would be driven by
persisting antigen, in this case citrullinated proteins.36
Therefore, once the antigenic load is reduced through effective
inflammatory treatment, IgG4 ACPA levels drop whereas IgG1
levels remain relatively stable. To substantiate this hypothesis,
it would be of interest to study ACPA subclass responses in
patients treated with B-cell depletion therapy. Plasma cells do
not express the target antigen (CD-20) on their surface and thus
rituximab may deplete short-lived plasma cells by targeting the
B-cell compartment from which they arise, whereas long-lived
plasma cells may be less affected. Interestingly, Thurlings et al37
have recently shown a direct correlation between clinical
response, a decrease in serum IgG ACPA levels and a lower
number of synovial plasma cells after rituximab treatment,
suggesting that short-lived synovial plasma cells play a role in
local ACPA production.
In summary, RA patients treated with TNF-blocking agents
show a reduction in ACPA subclass levels. This reduction is seen
predominantly in those responding to treatment and is more
pronounced for IgG4 than for IgG1. This may reflect a
disruption of the chronic antigenic stimulation of ACPA in
the rheumatic joint and/or a direct effect of anti-TNF treatment
on IgG4 ACPA synthesis. Further research is necessary to
substantiate this hypothesis.
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